We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Clinical Crossroads | Clinician's Corner

A 50-Year-Old Man With Hepatitis C and Cirrhosis Needing Liver Transplantation

Douglas W. Hanto, MD, PhD, Discussant
JAMA. 2003;290(24):3238-3246. doi:10.1001/jama.290.24.3238.
Text Size: A A A
Published online


DR SHIP: Mr G is a 50-year-old man who has had liver disease for about 12 years. He lives near Boston with his wife and children and is a partner in a small industrial firm. He has managed care insurance.

During a routine life insurance evaluation in 1991, Mr G was found to have abnormal liver function test results and was diagnosed with non-A, non-B hepatitis. Liver biopsy showed mild periportal inflammation. In 1995, he was found to have antibodies to hepatitis C. He was treated with interferon and ribavirin but did not improve. A liver biopsy in 2001 revealed grade II to III inflammation, stage IV fibrosis. He was subsequently treated with pegylated interferon and ribavirin and again did not improve. In 2001, he developed transient ascites and encephalopathy, with unsteady gait and forgetfulness. In 2002, Mr G bled from esophageal varices and underwent a transjugular intrahepatic portosystemic shunt (TIPS) procedure, requiring revision 1 week later. Since that time, he has been on the liver transplant waiting list.

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview


Figure 1. Trends in Liver Transplant Waiting List and Transplantation
Graphic Jump Location
Data from the United Network for Organ Sharing shows the growth in the number of patients on the waiting list for liver transplantation and the number of patients added to the list each year compared with the number of deceased donors and the number of deceased donor liver transplants performed in the United States (1993-2002).10
Figure 2. Reported Deaths and Annual Death Rates: Liver Transplantation Waiting List
Graphic Jump Location
Data from the United Network for Organ Sharing shows that although the number of deaths on the list has increased, reflecting the growth of the waiting list, the death rate per 1000 patient-years at risk has decreased.10
Figure 3. Mechanisms of Action of Immunosuppressive Drugs
Graphic Jump Location
MHC indicates major histocompatibility complex; IL, interleukin. Immunologic events from the time of liver transplantation to the development of rejection are summarized above. The sites of action of several immunosuppressive drugs are noted. Because different sites can be targeted with multidrug regimens, prevention of rejection can be accomplished with lower drug dosages thereby reducing adverse effects.
Figure 4. Prognosis After Liver Transplantation
Graphic Jump Location
Patient and graft survival 1, 3, and 5 years after liver transplantation in all patients compared with patients 50 to 64 years of age.10




You need to register in order to view this quiz.
Submit a Response


Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 2

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Evidence to Support the Update

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Evidence Summary and Review 2